Biotron Directors Lift Holdings Through Rights Issue Participation

Biotron ( (AU:BIT) ) has shared an update.

Biotron Limited has notified the ASX of changes in directors’ interests in the company’s securities, in compliance with listing requirements for disclosure of director shareholdings. The filing shows chairman Michael J. Hoy increased his indirect holding via Umbiram Pty Limited by acquiring additional ordinary shares and attaching options through participation in a rights issue, a move that modestly lifts insider ownership and signals continued director support for the company’s capital-raising activities.

More about Biotron

Biotron Limited is an Australian-listed biotechnology company focused on developing antiviral therapies, with its shares traded on the ASX. The company operates within the life sciences sector and targets unmet medical needs in viral diseases through proprietary drug discovery and development programs.

YTD Price Performance: -38.89%

Technical Sentiment Signal: Sell

Current Market Cap: A$7.23M

Learn more about BIT stock on TipRanks’ Stock Analysis page.